Pro-Dex (NASDAQ:PDEX – Get Free Report) had its price target boosted by equities researchers at Ascendiant Capital Markets from $74.00 to $80.00 in a report released on Monday, Benzinga reports. The firm presently has a “buy” rating on the medical instruments supplier’s stock. Ascendiant Capital Markets‘s target price would indicate a potential upside of 21.84% from the company’s current price.
A number of other equities analysts also recently issued reports on PDEX. Weiss Ratings raised shares of Pro-Dex from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, November 10th. Zacks Research lowered shares of Pro-Dex from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 9th. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, Pro-Dex currently has a consensus rating of “Moderate Buy” and an average target price of $80.00.
Read Our Latest Analysis on Pro-Dex
Pro-Dex Stock Performance
Shares of Pro-Dex stock opened at $65.66 on Monday. The stock has a fifty day simple moving average of $65.04 and a 200 day simple moving average of $57.67. Pro-Dex has a 12-month low of $28.81 and a 12-month high of $77.00. The company has a market capitalization of $210.11 million, a P/E ratio of 17.99 and a beta of 0.12. The company has a current ratio of 4.19, a quick ratio of 2.49 and a debt-to-equity ratio of 0.25.
Pro-Dex (NASDAQ:PDEX – Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The medical instruments supplier reported $0.92 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. The business had revenue of $20.56 million during the quarter, compared to analyst estimates of $20.40 million. Pro-Dex had a return on equity of 26.18% and a net margin of 15.12%. On average, sell-side analysts anticipate that Pro-Dex will post 3.09 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, CEO Kirk Richard Lee Van, Jr. sold 765 shares of the company’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $59.36, for a total value of $45,410.40. Following the transaction, the chief executive officer owned 79,228 shares in the company, valued at approximately $4,702,974.08. This represents a 0.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Alisha Charlton sold 2,300 shares of the stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $61.30, for a total value of $140,990.00. Following the transaction, the chief financial officer directly owned 21,870 shares of the company’s stock, valued at approximately $1,340,631. This trade represents a 9.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 22,300 shares of company stock worth $1,351,657 in the last ninety days. 48.00% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Pro-Dex
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Global Retirement Partners LLC boosted its position in Pro-Dex by 7,790.1% during the third quarter. Global Retirement Partners LLC now owns 78,901 shares of the medical instruments supplier’s stock worth $5,444,000 after purchasing an additional 77,901 shares during the period. Punch & Associates Investment Management Inc. increased its stake in shares of Pro-Dex by 2.9% in the first quarter. Punch & Associates Investment Management Inc. now owns 61,735 shares of the medical instruments supplier’s stock worth $3,032,000 after purchasing an additional 1,735 shares in the last quarter. Pekin Hardy Strauss Inc. increased its stake in shares of Pro-Dex by 38.2% in the third quarter. Pekin Hardy Strauss Inc. now owns 22,800 shares of the medical instruments supplier’s stock worth $1,573,000 after purchasing an additional 6,300 shares in the last quarter. Ellsworth Advisors LLC bought a new stake in shares of Pro-Dex in the third quarter valued at approximately $1,166,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Pro-Dex in the second quarter valued at approximately $678,000. 15.28% of the stock is currently owned by institutional investors.
Pro-Dex Company Profile
Pro-Dex, Inc. designs, develops and manufactures powered surgical instruments and related accessories, with a focus on devices used in orthopedic procedures. Its products include surgical handpieces and drivers, along with the components and systems that support their operation. The company also provides engineering, product development and manufacturing services to medical device companies. Its work can span the product lifecycle, from design and prototyping to production and servicing. Founded in 1978, Pro-Dex is headquartered in Irvine, California, and serves customers in the United States and international markets.
Featured Stories
- Five stocks we like better than Pro-Dex
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.
